Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes

Blood

Volumn 113, Issue 13, 2009, Pages 2888-2894

  Mielcarek, Marco ^a,b   Storer, Barry E ^a,b   Boeckh, Michael ^a,b   Carpenter, Paul A ^a,b   McDonald, George B ^a,b   Deeg, H Joachim ^a,b   Nash, Richard A ^a,b   Flowers, Mary E D ^a,b   Doney, Kristine ^a,b   Lee, Stephanie ^a,b   Marr, Kieren A ^a,b   Furlong, Terry ^a   Storb, Rainer ^a,b   Appelbaum, Frederick R ^a,b   Martin, Paul J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B LIPID COMPLEX; BECLOMETASONE DIPROPIONATE; BUSULFAN; CEFTAZIDIME; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; IMIPENEM; LEVOFLOXACIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VANCOMYCIN; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; INFECTION RISK; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYCOSIS; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 63849343227     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-168401     Document Type: Article

References (29)

1. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia [review]. Blood. 1995;86:813-818.
2. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
3. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75:1024-1030.
4. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340-352.
5. Storb R, Deeg HJ, Whitehead J, et al. Methotrex- ate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
6. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus- host disease: initial treatment. Blood. 1990;76:1464-1472.
7. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus- host disease: secondary treatment. Blood. 1991;77:1821-1828.
8. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10:655-668.
9. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multi- center randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92:2288-2293.
10. Roy J, McGlave PB, Filipovich AH, et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant. 1992;10: 77-82.
11. Hings IM, Severson R, Filipovich AH, et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation. 1994;58:437-442.
12. Cragg L, Blazar BR, DeFor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:441-447.
13. Bacigalupo A, Van Lint MT, Frassoni F, et al. High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut. 1983;46:125-132.
14. Kanojia MD, Anagnostou AA, Zander AR, et al. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation. 1984;37:246-249.
15. Kendra J, Barrett AJ, Lucas C, et al. Response of graft versus host disease to high doses of methyl- prednisolone. Clin Lab Haematol. 1981;3:19-26.
16. Oblon DJ, Felker D, Coyle K, Myers L. High-dose methylprednisolone therapy for acute graft-ver- sus-host disease associated with matched unrelated donor bone marrow transplantation. Bone Marrow Transplant. 1992;10:355-357.
17. McDonald GB, Bouvier M, Hockenbery DM, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology. 1998;115:28-35.
18. Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral be- clomethasone dipropionate as a prednisone- sparing therapy for gastrointestinal graft-versus- host disease. Blood. 2007;109:4557-4563.
19. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus- tumor effects. Blood. 2001;97:3390-3400.
20. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021-2030.
21. Bucaneve G, Micozzi A, Menichetti F, et al. Levo- floxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977-987.
22. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 anti- genemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients [letter to editor]. Blood. 1999;93:1781-1782.
23. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood. 2001;98:573-578.
24. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immu- nocompromised patients with cancer and hema- topoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
25. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
26. GooleyTA, Leisenring W, CrowleyJ, StorerBE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
27. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive Aspergillosis following hematopoi- etic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531-540.
28. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoste- roids. Rev Infect Dis. 1989;11:954-963.
29. Wald A, Leisenring W, van Burik J-A, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459-1466.